Revised forecast
Fiscal year ending March 2026 · Full yearPrevious forecast published 9 May 2025The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
The core rental business performed steadily, while the dispensing pharmacy business saw an increase in prescription unit prices due to a rise in prescriptions for high-priced pharmaceuticals. Revenue from the bedding and linen supply business also performed strongly, supported by increased utilization of customer facilities such as hotels and price revisions. In the silver business, costs were reduced through more efficient operation of rental equipment. Although impairment losses are expected to be recorded on land at the Company's Saitama Plant and certain stores in the dispensing pharmacy business, net income is now expected to exceed the previous forecast due to strong operating profit and ordinary profit.
Impairment losses are expected to be recorded on land at the Company's Saitama Plant and certain stores in the dispensing pharmacy business, among other assets. Amount: Not disclosed.
| Item | Details |
|---|---|
| Net Sales | ¥157,976 million → ¥159,635 million（+1.1%） |
| Operating profit | ¥8,216 million → ¥9,335 million（+13.6%） |
| Ordinary income | ¥8,590 million → ¥10,017 million（+16.6%） |
| Profit attributable to owners of the parent | ¥5,499 million → ¥6,058 million（+10.2%） |
| Net income per share | 178.24 yen and sen → 185.27 yen and sen |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 9 May 2025 |
| Previous-period results | Revenue: ¥149,542 million; operating profit: ¥8,193 million; ordinary profit: ¥8,825 million; profit attributable to owners of the parent: ¥4,729 million; earnings per share: ¥138.97 |
| Reason for the revision | The core rental business performed steadily, while the dispensing pharmacy business saw an increase in prescription unit prices due to a rise in prescriptions for high-priced pharmaceuticals. Revenue from the bedding and linen supply business also performed strongly, supported by increased utilization of customer facilities such as hotels and price revisions. In the silver business, costs were reduced through more efficient operation of rental equipment. Although impairment losses are expected to be recorded on land at the Company's Saitama Plant and certain stores in the dispensing pharmacy business, net income is now expected to exceed the previous forecast due to strong operating profit and ordinary profit. |
| Details and amount of extraordinary loss | Impairment losses are expected to be recorded on land at the Company's Saitama Plant and certain stores in the dispensing pharmacy business, among other assets. Amount: Not disclosed. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In addition to revenue from the core rental business, dispensing pharmacy business, and bedding and linen supply business progressing ahead of plan, costs were successfully reduced in the silver business through more efficient operation of rental equipment. Although impairment losses are expected to be recorded, net income was also revised upward due to strong operating profit and ordinary profit.